From GlobeNewswire: 2025-05-28 22:40:00

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced the pricing of an underwritten public offering of 46,868,687 shares of its common stock at $2.75 per share, with gross proceeds expected to be approximately $200.0 million. The offering is expected to close on or about May 30, 2025. Jefferies, BofA Securities, Piper Sandler, and Barclays are acting as joint book-running managers. Taysha Gene Therapies is focused on developing AAV-based gene therapies for severe monogenic diseases of the central nervous system, with its lead clinical program TSHA-102 in development for Rett syndrome.

A shelf registration statement was filed with the SEC on December 13, 2024, and declared effective on December 20, 2024. The offering is being made by written prospectus and prospectus supplement. Forward-looking statements in the press release outline the potential impact of TSHA-102 and other product candidates. Risks and uncertainties related to Taysha’s business are detailed in SEC filings. Hayleigh Collins is the Senior Director of Corporate Communications and Investor Relations at Taysha Gene Therapies, Inc. Media inquiries can be directed to Carolyn Hawley at Inizio Evoke.



Read more at GlobeNewswire: Taysha Gene Therapies Announces Pricing of Public Offering